BCL2 and acute myeloid leukemia: Briefly, we suggest for AML patients with high BCL-2 levels the venetoclax + I-BET151 combination, which decreases BCL2 gene transcription and BCL-2 protein levels, whereas for AML patients with high MCL-1 levels, the venetoclax + sunitinib combination would be considered for its ability to affect MCL-1 levels.